3 High Growth GLP-1 Biotech Winners to Buy in July

GLP-1 opportunity set is expanding ahead of 2026 oral launches: Eli Lilly (LLY) reported Q1 2026 EPS of $8.55 vs $6.79 consensus on revenue of $19.80B (+56% YoY) and raised full-year guidance to $82.0–$85.0B revenue and $35.50–$37.00 non-GAAP EPS. Key upside is oral formulary expansion led by Foundayo (FDA approval), while downside risks include realized prices down 13% in Q1 2026 and China pricing pressure tied to Mounjaro’s NRDL addition. Novo Nordisk (NVO) offers valuation-driven mean reversion but faces share loss to Lilly (shares ~28% lower YoY), and Viking Therapeutics (VKTX) is a high-risk pre-revenue Phase 3/Phase 2 catalyst play with a $359.64M 2025 net loss and $706M cash at year-end 2025.

Analysis

The equity setup is less about "GLP-1 winners" and more about who controls access, adherence, and reimbursement. LLY is the clearest beneficiary because it can use the oral channel to widen the patient funnel while forcing competitors into discounting; the second-order effect is margin pressure across the category as convenience becomes a competitive weapon rather than a pure volume tailwind. That said, the stock already embeds a premium for execution, so upside now depends more on mix/pricing resilience than on simple prescription growth.

NVO looks like the cleaner mean-reversion trade, but only if US share erosion stops before the market starts modeling a permanent reset in peak earnings power. The risk is that the current valuation is not a bargain multiple but a signal that investors are discounting a multi-quarter rebate war and slower international pricing too; if that proves true, the name can remain cheap for much longer than bulls expect. A stabilization read-through would also matter for contract manufacturers and obesity-adjacent suppliers that have been trading as if only one platform can win.

VKTX is the pure optionality leg: it benefits most if the market starts paying for differentiated dosing convenience, but it also has the highest dilution and trial-failure convexity. The key contrarian point is that the market may be overestimating how much an oral pill changes behavior in the near term; reimbursement and tolerability will likely matter more than headline formulation, which argues for smaller sizing and tighter catalyst-based timing.

Key Decisions for Investors

• Long LLY / short NVO as a 1-3 month pair trade into the next launch and share-read cycle; thesis works if Lilly keeps monetizing convenience while Novo fails to arrest US erosion. Falsify on NVO share stabilization or a sharp LLY pricing/margin miss.
• Use NVO only as a selective contrarian long, sized small, on evidence of prescription-share stabilization or margin guidance resilience; this is a value-recovery trade, not a momentum trade. Exit if the market starts marking down 2027 earnings again.
• Buy VKTX call spreads into Q3 2026 catalyst windows rather than common stock; the asymmetry is attractive only if you want defined-risk exposure to positive phase-3/maintenance data. Falsify on any sign of protocol slippage, weaker-than-expected readouts, or financing need.
• If forced to own only one name, prefer LLY on pullbacks over chasing VKTX strength; LLY has the most visible cash-flow conversion and the least binary risk over the next 1-3 months.
• Set an alert on LLY realized pricing and NVO US share metrics; if pricing continues to deteriorate faster than volume grows, the entire GLP-1 basket can de-rate despite headline demand growth.